COSENTYX DRUG MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Cosentyx Drug Market Size and Trends

Global cosentyx drug market is estimated to be valued at USD 5.32 Bn in 2024, and is expected to reach USD 8.74 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.3% from 2024 to 2031.

To learn more about this report, Request sample copy

The market is expected to witness growth at a steady rate during the forecast period. Rising cases of various autoimmune and inflammatory diseases such as psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and others is expected to drive the market growth. Cosentyx has demonstrated high efficacy and a well-tolerated safety profile. However, patent expiry of the drug in 2027 may impede the market's growth to some extent once cheaper biosimilars enter the market. Overall, increasing disease awareness and expanding treatment rates across developing nations will boost demand for Cosentyx during the forecast period.

Unmet Medical Need for Effective Treatment Options

The options to effectively treat psoriatic arthritis were quite limited as many patients did not respond well or had adverse reactions to conventional treatments such as methotrexate and anti-TNF drugs. Cosentyx was one of the first innovative biologic drugs that arrived in the market to address this unmet need through a novel mechanism of action. It works by selectively inhibiting the cytokine Interleukin-17A, which is a major pathogenic driver of psoriatic inflammation. In several Phase 3 clinical trials, Cosentyx demonstrated high efficacy and a fast onset of action in treating both the skin manifestations and joint symptoms associated with psoriatic arthritis. It provided long-lasting remissions and significantly improved physical function and quality of life. Moreover, Cosentyx exhibited a cleaner safety and tolerability profile relative to other drugs in its category.

To learn more about this report, Request sample copy

Increasing prevalence of psoriatic arthritis across the world has been a major factor contributing to growth of global cosentyx drug market. Psoriatic arthritis is a chronic inflammatory disease that results in pain, stiffness, and swelling in and around the joints. It commonly occurs in patients suffering from plaque psoriasis, a distressing and persistent form of psoriasis. According to a study published by CreakyJoints in October 2020, around 30% of people living with plaque psoriasis may eventually develop psoriatic arthritis.